A new Lancet Psychiatry review examined 54 randomized trials of cannabinoids for mental disorders and substance use disorders, and the evidence was thinner than many public claims suggest. A few outcomes showed signals, especially in cannabis use disorder, sleep-time outcomes in insomnia, tic severity, and autism-related measures, but much of the literature remained low certainty and short-term. This physician-guided review explains what the paper actually found, what it did not test, and how to think about the gap between clinical enthusiasm and evidence quality.
Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years
Endocannabinoid system clinical research from a 2026 conference links THC and CBD beverages to reduced alcohol use in adults after five years.
Cannabis Rescheduling Update: Advocates Eye AG Bondi Hearing for Status Report
Cannabis rescheduling could ease research restrictions and reduce tax burdens on the industry, but it won’t make recreational marijuana legal—only Congress can do that. Reform advocates are watching Attorney General Pam Bondi’s scheduled appearance before the House Judiciary Committee for an update on where cannabis rescheduling stands. Pennsylvania House Democrats are calling on the GOP Senate to follow their lead on legalization, as Gov.